Impact of Egg Consumption on Carotenoid and Vitamin D Bioavailability in Pre- and Post-menopausal Women
1 other identifier
interventional
20
1 country
1
Brief Summary
The 2010 Dietary Guidelines for Americans emphasizes consumption of 4.5 cups of fruits and vegetables daily but the average intake of US adults is only 2.6 cups. This low consumption of fruits and vegetables results in a limited availability of certain nutrients found in these foods such as carotenoids. Dietary carotenoids have health-promoting properties and are known to fight against disease. Although, maintaining adequate vitamin D status is critical for overall skeletal health and the prevention of osteoporosis, vitamin D insufficiency is also widespread in the United States. Eggs, egg yolk in particular, are known to be a good source of lipid and may improve the absorption of carotenoids and vitamin D found in co-consumed vegetables in young and older women. Therefore, the investigators are interested to see if consuming eggs with cooked vegetables will increase carotenoids and vitamin D absorption.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Dec 2015
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2015
CompletedFirst Submitted
Initial submission to the registry
February 4, 2016
CompletedFirst Posted
Study publicly available on registry
February 10, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2017
CompletedJanuary 11, 2018
January 1, 2018
1.4 years
February 4, 2016
January 9, 2018
Conditions
Outcome Measures
Primary Outcomes (2)
Contents of total and individual carotenoids in triglyceride-rich lipoprotein fractions
composite 0-10 h area under the curve of total and individual carotenoids (lutein, zeaxanthin, alpha-carotene, beta-carotene, lycopene) in triglyceride-rich lipoprotein fractions (all units are nmol/L x 10 hours)
From hour 0 to hour 10
Vitamin D content in in triglyceride-rich lipoprotein fractions
composite 0-10 h area under the curve of vitamin D2, vitamin D3, 25(OH)D2, and 25(OH)D3 in triglyceride-rich lipoprotein fractions (all units are nmol/L x 10 hours)
From hour 0 to hour 10
Study Arms (2)
Egg consumption
EXPERIMENTALConsuming sautéed vegetables and 3g canola oil with 100g (2 large eggs) of whole eggs
Control
PLACEBO COMPARATORConsuming sautéed vegetables and 3g canola oil without eggs
Interventions
Subjects will consume a carefully portioned sautéed vegetables and 3g canola oil with 100g (2 large eggs) of whole eggs
Subjects will consume a carefully portioned sautéed vegetables and 3g canola oil.
Eligibility Criteria
You may qualify if:
- Pre- (regularly menstruating, aged 19-45y) and post-menopausal (aged 60+y) females
- weight stable (± 3 kg in the past 3 months)
- constant habitual activity patterns within last 3 months
- no acute illness
- not diabetic or have chronic diseases known to influence lipid or energy metabolism
- blood 25(OH)D\>20 nmol/L
- non-smoking
- drinking no more than 2 alcoholic drinks per day
- not taking estrogen-based birth control or osteoporosis prevention or treatment medications in the past 3 months
- not taking lipid-lowering medications
You may not qualify if:
- Males
- age \<19 or age \>45y for pre-menopausal women and age \<60y for post-menopausal women
- weight change\>3 kg in the past 3 months
- exercising vigorously over the past 3 months
- intestinal disorders including lipid malabsorption or lactose intolerance
- abnormal liver or kidney function tests
- blood 25(OH)D\<20 nmol/L
- fasting blood glucose\>110 mg/dL
- smoking
- drinking more than 2 alcoholic drinks per day
- taking estrogen-based birth control or osteoporosis prevention or treatment medications in the past 3 months
- taking lipid-lowering medications affecting plasma cholesterol concentration
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Purdue Clinical Research Center
West Lafayette, Indiana, 47907, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Wayne W Campbell, Ph.D.
Purdue University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- INVESTIGATOR
- Purpose
- OTHER
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Wayne Campbell, Ph.D.
Study Record Dates
First Submitted
February 4, 2016
First Posted
February 10, 2016
Study Start
December 1, 2015
Primary Completion
May 1, 2017
Study Completion
August 1, 2017
Last Updated
January 11, 2018
Record last verified: 2018-01